Comparison 3. Dihydroartemisinin‐piperaquine (DHA‐PPQ) plus daily cotrimoxazole (CTXp) versus placebo plus CTXp.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Maternal peripheral parasitaemia at delivery (amplification techniques)	3	1517	Risk Ratio (M‐H, Fixed, 95% CI)	0.59 [0.31, 1.11]
3.2 Maternal peripheral parasitaemia at delivery (microscopy)	3	1614	Risk Ratio (M‐H, Random, 95% CI)	0.77 [0.17, 3.58]
3.3 Maternal anaemia at delivery (< 11g/dL)	2	1454	Risk Ratio (M‐H, Random, 95% CI)	0.95 [0.82, 1.10]
3.4 Placental malaria (any test)	3	1571	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.42, 1.49]
3.5 Placental malaria (histopathologic analysis)	3	1570	Risk Ratio (M‐H, Fixed, 95% CI)	0.67 [0.50, 0.90]
3.6 Maternal peripheral parasitaemia during pregnancy (any test)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.7 Clinical malaria episodes during pregnancy	3		Rate Ratio (IV, Fixed, 95% CI)	0.56 [0.19, 1.67]
3.8 Mean haemoglobin at delivery (g/dL)	2	978	Mean Difference (IV, Random, 95% CI)	‐0.18 [‐0.51, 0.15]
3.9 Maternal severe anaemia at delivery (< 7g/dL)	2	1454	Risk Ratio (M‐H, Fixed, 95% CI)	1.42 [0.75, 2.67]
3.10 Low birth weight (< 2500 g)	3	1695	Risk Ratio (M‐H, Fixed, 95% CI)	1.13 [0.87, 1.48]
3.11 Mean birth weight (g)	2	1498	Mean Difference (IV, Fixed, 95% CI)	‐61.39 [‐112.11, ‐10.68]
3.12 Cord blood parasitaemia (microscopy)	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.13 Cord blood parasitaemia (loop‐mediated isothermal amplification)	1	190	Risk Ratio (M‐H, Fixed, 95% CI)	Not estimable
3.14 Prematurity	3	1577	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.56, 1.94]
3.15 Severe adverse events during pregnancy	2	1450	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.61, 1.25]
3.16 Foetal loss	3	1610	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.68, 1.90]
3.17 Congenital malformations	3	1592	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.39, 3.06]
3.18 Maternal mortality	2	1440	Risk Ratio (M‐H, Fixed, 95% CI)	4.99 [0.24, 103.62]
3.19 Neonatal mortality	2	1467	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.39, 2.72]
3.20 Adverse events: headache	2	1447	Risk Ratio (M‐H, Fixed, 95% CI)	1.60 [0.62, 4.10]
3.21 Adverse events: gastrointestinal disorders after first IPTp dose	2	1447	Risk Ratio (M‐H, Random, 95% CI)	1.42 [0.51, 3.98]
3.22 Adverse events: dizziness after first IPTp dose	2	1447	Risk Ratio (M‐H, Random, 95% CI)	1.25 [0.26, 5.96]
3.23 Mother‐to‐child transmission of HIV	2	1063	Risk Ratio (M‐H, Fixed, 95% CI)	1.54 [0.26, 9.19]
3.24 Undetectable HIV viral load at delivery	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only